Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on CVS Caremark Corporation

Share:
Related CVS
The Difference Between Mylan's EpiPen And Generic Offerings
Will Walgreens Start The New Year Off Strong?
One Step Closer To Financial Freedom: My 2016 Income Review (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on CVS Caremark Corporation (NYSE: CVS), and raised its price target from $50.00 to $54.00.

Jefferies noted, “CVS reported another strong Q fulfilling our 2012 thesis that it would beat and raise throughout the year. The looming question is what CVS will do for an encore. While compares get more difficult, CVS' advantaged business model, significant cash flow and strong management team suggest FY13 will be another successful year, likely driven by a number of smaller catalysts. This, plus a modest valuation, implies the equity is undervalued.”

CVS Caremark Corporation closed on Tuesday at $46.88.

Latest Ratings for CVS

DateFirmActionFromTo
Dec 2016JefferiesAssumesBuyHold
Oct 2016UBSInitiates Coverage onBuy
Oct 2016Bank of AmericaMaintainsBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!